Clinical Trial Update: Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function [NA]

View source ↗

Summary

Clinical trial evaluating Lutetium-177 PSMA therapy in patients with compromised renal and/or bone marrow function is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lu-177 PSMA (Lutetium-177-labeled PSMA ligand)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lu-177 PSMA | NA | Status: RECRUITING